Next-Gen Alzheimer’s Biomarker Profiling: Human Beta-Amyloid 1-40 & 1-42 Detection Kit (Digital Immunochip Method)
Alzheimer’s disease (AD) pathology initiates decades prior to the overt onset of memory loss and cognitive decline. Pathophysiologically marked by the accumulation and aggregation of amyloid-beta plaques in brain parenchyma, definitive diagnosis has historically relied upon Amyloid Positron Emission Tomography (PET) or cerebrospinal fluid (CSF) analysis via lumbar puncture.
The Human Beta-Amyloid 1-40 (Aβ40) and 1-42 (Aβ42) Detection Kits—developed by iomics Biosciences and distributed by DOIT Scientific JSC—represent an IVD paradigm shift. Harnessing cutting-edge Digital Immunochip Technology, this solution enables reliable, ultra-sensitive quantification of AD biomarkers directly from peripheral blood plasma.
1. The Clinical Significance of the Plasma Aβ42/Aβ40 Ratio
While Aβ42 monomers are prone to oligomerization and plaque formation, individual biomarker concentrations in peripheral blood can fluctuate across demographics. Consequently, the Aβ42/Aβ40 ratio has emerged as the recognized diagnostic standard:
- Robust PET Correlation: A reduced plasma Aβ42/Aβ40 ratio demonstrates high diagnostic concordance with positive cerebral amyloid PET scans.
- True Non-Invasiveness: Replaces complex, traumatic CSF draws with a standard phlebotomy procedure.
- 10–20 Year Early Warning: Identifies preclinical AD stages, opening a therapeutic window for disease-modifying anti-amyloid therapies.
2. Key Competitive Advantages of the Digital Immunochip Platform
2.1. Femtogram-Level Sensitivity (1,000x Greater Than ELISA)
Biomarkers exist in plasma at concentrations orders of magnitude lower than in CSF. The Digital Immunochip platform achieves a detection limit in the femtogram (fg/mL) range, providing 1,000-fold greater sensitivity than conventional microplate ELISA assays.
2.2. Single-Molecule Digital Counting with AI Integration
Utilizing magnetic capture micro-beads paired with ultra-dense microfluidic chips, individual biomarker-antibody complexes are physically partitioned and digitally imaged. Integrated AI algorithms quantify single fluorescent molecules independently, eliminating manual readout variance and cross-reactivity noise.
2.3. Micro-Volume Requirement: 25 μL Plasma
Conserving precious patient specimens, the assay requires an input of merely 25 μL of human plasma, rendering it optimal for elderly and fragile patients.
2.4. Rapid Diagnostic Turnaround (20–30 Minutes)
Conventional immunoassays frequently require several hours of incubation and washing steps. The automated Digital Immunochip workflow delivers validated quantitative readouts within 20 to 30 minutes, facilitating rapid clinical decision-making.
2.5. Seamless Automation on the Inspirer DX Analyzer
Engineered for end-to-end compatibility with the Inspirer DX Analyzer, the kit guarantees rigorous intra- and inter-assay precision (low CV%), streamlining laboratory accreditation (ISO 15189 / CAP).
3. Technical Specifications
| Parameter | Specification |
| Product Names | Human β-Amyloid 1-40 Detection Kit & Human β-Amyloid 1-42 Detection Kit |
| Assay Methodology | Digital Immunochip Microfluidic Technology |
| Readout Principle | Digital Single-Molecule Fluorescence Counting |
| Specimen Matrix | Human Plasma |
| Required Sample Volume | 25 μL |
| Time to Result | 20 – 30 minutes |
| Kit Packaging | 48 tests/kit or 96 tests/kit |
| Instrument Platform | Inspirer DX Analyzer |
| Manufacturer | iomics Biosciences |
| Authorized Distributor | DOIT Scientific Joint Stock Company |
4. Target Clinical Applications
- Preventive Health Screening: Routine baseline evaluations for individuals aged 50+ or those with a familial predisposition to dementia.
- Mild Cognitive Impairment (MCI) Stratification: Distinguishing AD-driven cognitive deficits from vascular dementia, frontotemporal disorders, or pseudodementia.
- Clinical Trials & Therapy Monitoring: Monitoring amyloid clearance kinetics during anti-amyloid monoclonal antibody treatments.
5. Request Technical Documentation & Commercial Inquiries
Upgrade your institution’s neurodiagnostic capabilities with DOIT Scientific JSC.
- 🏢 Address: No. 645, Group 39, Zone 4, Ha Lam Ward, Quang Ninh Province, Vietnam
- 📞 Direct Line / Hotline: (+84) 988.01.68.01
- 📧 Email: info@doitvn.com
- 🌐 Website: https://doitvn.com
